Lunit’s Acquisition of Volpara | An Advanced Leap in Cancer Diagnostics
Lunit’s acquisition of Volpara at AUD 1.15 per share marks a pivotal move in cancer diagnostics. The Scheme Implementation Agreement targets Volpara’s AI-enabled solutions, expanding Lunit’s global presence. Volpara’s 100 million mammogram images promise…
Continue Reading